当前位置：文档之家 › 《加州65提案》(California Proposition 65-CA Prop 65)

《加州65提案》(California Proposition 65-CA Prop 65)

  • 格式：pdf
  • 大小：321.56 KB
  • 文档页数：21

下载文档原格式

  / 21

合集下载

加利福尼亚州的65号提案

加利福尼亚州的65号提案

加利福尼亚州的65号提案加利福尼亚州的65号提案是一项重要的法案，旨在改革州内的退休和福利计划。

该提案于2020年11月大选中获得通过，并于2021年1月生效。

该提案主要涉及加州公务员的养老金制度和福利计划，以及相关税收和财政方面的调整。

该提案的核心是旨在解决加利福尼亚州面临的退休和福利计划的可持续性问题。

根据提案，公务员的养老金和其他福利待遇将会作出一些改变。

其中包括增加退休年龄、调整退休金计算公式、增加个人自愿缴费和减少福利待遇等。

具体来说，该提案将增加加州公务员的退休年龄。

此前，退休年龄为50岁，该提案将逐步提高退休年龄至57岁。

这样做的目的是延长公务员的工作时间，以缓解养老金制度的压力。

此外，提案还调整了退休金的计算公式，使之更加与实际工资和工作年限相匹配。

该提案还要求公务员增加个人自愿缴费。

以前，公务员只需要缴纳一部分养老金，剩余部分由政府支付。

而该提案要求公务员增加个人缴费，以减轻政府的负担。

此外，提案还规定了一些福利的减少措施，包括减少医疗保险福利和其他补助金。

除了改革公务员的养老金和福利计划外，该提案还涉及到相关的税收和财政调整。

提案要求增加一系列税收，以增加政府的财政收入，用于支付养老金和其他福利。

这些税收包括对高收入者的额外税收以及对大型企业的税收调整。

该提案引发了一些争议。

支持者认为该提案是必要的改革，可以保护州内的养老金和福利体系，确保其可持续性。

然而，反对者则认为该提案过于严厉，会对公务员的权益造成不公平的打击。

总之，加利福尼亚州的65号提案是一项重要的法案，旨在改革州内的退休和福利计划。

该提案涉及到公务员的养老金制度和福利待遇的改变，以及相关税收和财政方面的调整。

尽管该提案引发了一些争议，但它反映了政府为解决养老金问题所采取的努力，以确保加利福尼亚州的福利体系的可持续性。

加州65法案

加州65法案

加州65号提案加州65号提案，即《1986年饮用水安全与毒性物质强制执行法》，于1986年11月颁发，其宗旨是保护美国加州居民及该州的饮用水水源，使水源不含已知可能导致癌症、出生缺陷或其他生殖发育危害的物质，并在出现该类物质时如实通知居民。

加州65号提案负责监管加州已知可能导致癌症或生殖毒性的化学品。

目前已有700多种化学品被列为该类化学品受到监管。

根据该法规规定，化学品清单至少每年修订和再版一次。

65号文件关于玻璃器皿和陶瓷品的要求1986年颁布的安全饮用水和有毒物执行法，即65号文件，要求在加州任何会排出致癌或再生毒性的化学物质的商品上标有警告。

列出的化学物质中包括铅和镉。

法院对最近一起65号文件提出的诉讼做出了一项新的试行判决，判定被告必须重新制作那些外部装饰含有铅和镉的玻璃器皿和陶瓷品。

达到再制作标准的产品可以在加州出售而无需标有65号文件所要求的警告。

产品包括：• 用于食物或饮料储存、盛放的玻璃和陶瓷制品• 非食物或饮料用玻璃和陶瓷制品（日用品）外部装饰是指产品外部表面上着色的图形、设计及制作。

外部装饰包括延伸到边缘区的设计只能使用符合关于铅和镉的再制作标准的材料。

儿童产品必须符合一系列更严格的再制作标准。

对于不能达到再制作标准的产品，需在产品上标有65号文件要求的警告。

下面列出的是一项已达成共识的关于玻璃器皿和陶瓷器皿警告标识的的指导方针。

玻璃器皿所有儿童产品：外部装饰，包括边缘区，只能使用含有少于0.06的铅和0.48镉的装饰材料。

食品/饮料产品（边缘装饰过的）外部装饰，包括边缘区，只能使用含有少于0.06的铅和0.48镉的装饰材料。

所有延伸至边缘区的外部装饰只能使用无可检测的铅或镉的装饰材料（≤ 0.02%铅, ≤ 0.08%镉）。

非食品/饮料产品：在进行擦拭试验时（美国国立卫生研究所测试方法第9100号），外部装饰的铅必须少于1.0μg或镉少于8.0μg。

或者外部装饰，包括边缘区，只能使用含有少于0.06的铅和0.48镉的装饰材料。

美国加州65号法案(Proposition 65)与咖啡致癌案

美国加州65号法案(Proposition 65)与咖啡致癌案

美国加州65号法案（Proposition 65）与咖啡致癌案3月28日，美国加利福尼亚州洛杉矶县高等法院做出初步裁决，认定某咖啡企业没有能够按照加州65号法案（Proposition 65）的要求对其在加州出售的咖啡饮品上给消费者提供致癌警告。

包括中国在内的多个国际知名咖啡公司也同被列为本案被告，一时舆论大哗。

加州65号法案是什么？该法案对输美的食品企业意味着什么？咖啡又是否真的致癌呢？本文结合笔者作为美国食品安全律师的执业经验，针对以上3个问题分别进行解析。

加州65号法案是什么？加州65号法案的全名是《安全饮用水及有毒物质管控1986法案》（The Safe Drinking Water and Toxic Enforcement Act of 1986），顾名思义，其立法的根本目的在于保护加州饮用水源，以及减少人们暴露于可能导致癌症、出生缺陷或损害生殖系统的有毒物质中。

法案规定加州政府需公布一份已知的致癌或损害生殖健康的化学物质清单，并且每年更新。

从法案施行起至今，已经有超过950种有毒物质被列入此清单，其中包括丙烯酰胺及砷、汞、铅等多种重金属。

值得一提的是，该法案实质并不绝对禁止含有列入清单中有毒物质产品在加州销售――如果企业的产品会使加州居民接触到可能产生危害剂量的有毒物质，法案规定企业必需为消费者提供相应的“清晰和合理”的警告；反之，假如消费者接触到有害物质的剂量尚未超出安全水平，企业可以不用提供任何警告。

对于可能致癌的有害物质来说，安全水平的定义为在一生（70年）都持续接触该有毒物质的十万人中，不会有超过1个癌症案例的接触水平，而接触水平取决于产品所含相关有毒物质的浓度和消费者对特定产品的消费量。

如果判定需要为消费者提供警告，法案中提供多种方式供企业选择，常见的包括在食品标签上加附警告字句标签或在产品陈列处提供警告。

在线销售的产品，如果可以被身处加州的消费者购买，电商也有责任在交易完成前通过网络进行警示。

加州65号提案普洱

加州65号提案普洱

加州65号提案普洱
摘要：
1.加州65 号提案的概述
2.提案对普洱茶产业的影响
3.普洱茶的致癌风险
4.专家对提案的看法
5.提案实施后的市场反应
正文：
加州65 号提案是美国加州的一项法案，旨在保护公众免受有害物质的侵害。

这项提案要求企业在产品中含有特定有害物质时必须向公众发出警告。

近年来，这项提案的实施对普洱茶产业产生了重大影响。

普洱茶是中国云南省的一种特色茶，其独特的发酵过程使其具有独特的口感和营养价值。

然而，近年来有研究表明，普洱茶中可能含有致癌物质。

这使得加州65 号提案的实施对普洱茶产业产生了直接影响。

根据加州65 号提案，如果普洱茶中含有致癌物质，那么企业在销售普洱茶时必须向公众发出警告。

这使得一些普洱茶企业感到担忧，因为他们担心这会影响他们的销售。

然而，一些专家认为，加州65 号提案的实施对普洱茶产业来说并不是坏事。

他们认为，这会促使普洱茶企业加强产品质量管理，从而提高产品的质量和安全性。

在提案实施后，普洱茶市场出现了一些反应。

一些消费者对普洱茶的安全
性表示担忧，这导致了普洱茶的销售量下降。

然而，也有一些消费者认为，加州65 号提案的实施有助于保障他们的权益，因此他们对购买普洱茶更加放心。

总的来说，加州65 号提案的实施对普洱茶产业产生了复杂的影响。

一方面，它对普洱茶企业的生产和销售造成了一定的压力；另一方面，它也促使企业提高产品质量，从而提高产品的安全性和竞争力。

加州65陶瓷铅镉限量标准

加州65陶瓷铅镉限量标准

加州65陶瓷铅镉限量标准
加州65号提案（Proposition 65）是美国加利福尼亚州关于增加对可接触的有毒化学物质关注的提案。

加州65法案对陶瓷制品的检测项目主要关注的是铅和镉的含量。

根据该法案，如果陶瓷制品的铅含量超过规定限量，就需要在产品上附上关于外部装饰的警告字句。

具体的限量标准如下：
1. 扁平陶瓷餐具的食物接触面所释出的铅，浓度不超过0.226ppm。

2. 陶瓷空心餐具内部食物接触面所释出的铅，浓度不超过0.100ppm。

3. 陶瓷制品的边唇范围所释出的铅和镉的含量，要求分别不得超过每毫升0.050微克及每毫升
4.00微克。

此外，对于不能达到再制作标准的产品，需在产品上标有65号文件要求的警告。

对于儿童产品，加州65号提案还规定了更为严格的再制作标准。

ca65环保标准 砷

ca65环保标准 砷

CA65环保标准是指加州65号法案（California Proposition 65），它旨在保护加州居民免受化学品污染物的危害。

其中，砷作为一种常见的污染物质，受到了广泛关注。

本文将从砷的来源、危害、监管标准等方面展开详细介绍，以期帮助读者全面了解CA65环保标准对砷的相关规定。

一、砷的来源砷是一种广泛存在于自然界和人类活动中的化学元素，其存在形式多种多样。

天然砷主要存在于矿石和土壤中，而人为排放的砷则主要来自工业生产、燃煤、农药使用等渠道。

此外，砷还可通过地下水受到污染，成为饮用水中的一大隐患。

二、砷的危害砷被认为是一种潜在的致癌物质，长期暴露于砷可能导致多种健康问题，包括但不限于皮肤病变、肺部疾病、心血管疾病以及多种癌症。

特别是对于儿童和孕妇来说，砷污染的风险更为严重，易导致生长发育问题和儿童行为异常。

三、CA65环保标准对砷的监管根据CA65环保标准，加州政府已经规定了砷的发布限值，以保护公众免受砷污染的侵害。

根据该标准，任何产品中砷的含量若超过规定限值，则必须在产品上进行警示标识，提示消费者注意相关风险。

这意味着生产商需要对其产品中砷的含量进行严格管控，并对可能的风险向消费者做出明确提示。

四、遵守CA65环保标准的重要性遵守CA65环保标准对企业至关重要。

一方面，合规生产有助于企业建立良好的社会形象，提升消费者对产品的信任度；另一方面，遵守法规也有助于降低企业因环境问题而面临的法律风险和经济风险。

因此，企业应当高度重视CA65环保标准对砷的监管要求，加强生产过程中对砷污染的管控，确保产品符合相关标准。

五、加强监管与防范砷污染的措施除了企业自身的管理措施，政府部门也应加强对砷污染的监管力度，加大对工业排放、农药使用、饮用水等领域的监测与治理力度，确保砷污染得到有效控制。

同时，加强对砷污染相关知识的宣传教育，增强公众对砷污染的认识和防范意识，也是预防砷污染的重要举措。

六、结语砷作为一种常见的化学污染物质，其对人类健康的危害不容忽视。

reach ca prop65标准

reach ca prop65标准

文章标题：探讨CA Prop65标准下的产品安全与健康保障一、引言在现代社会，人们对产品的安全和健康问题越来越重视。

而在美国加州，Prop65标准作为一项法规规定，对产品的有害物质的使用和披露提出了严格的要求。

在本文中，我们将深入探讨CA Prop65标准，分析其对产品安全与健康保障的重要性和意义。

二、了解CA Prop65标准1. CA Prop65标准是什么？CA Prop65标准是指加州65号法案（Proposition 65），它于1986年通过并在1988年实施。

该法案要求在加州销售和分发的产品中，必须对其中的化学物质做出披露，特别是那些已知对健康造成潜在危害的化学物质。

这就意味着生产商需要在产品上明确标示可能存在的有害物质，同时向消费者提供相关信息，以便消费者做出知情决策。

2. CA Prop65标准的制定背景CA Prop65标准的制定背景源自对环境和健康的保护。

人们对于食品、饮用水、药品、化妆品、清洁产品和其他日常用品中的有害物质日益关注，因此有必要对产品中的化学成分进行全面的披露和警示，以保障公众的权益和健康安全。

3. CA Prop65标准的适用范围CA Prop65标准适用于加州州内销售和分发的产品，包括但不限于食品、药品、饮料、化妆品、家居用品、玩具、电子产品等。

对于涉及到的有害物质，标准明确了一份名单，产品中含有名单上的化学物质的情况需要进行披露。

三、CA Prop65标准对产品安全与健康保障的重要性1. 提升产品的透明度和可信度CA Prop65标准的实施，使消费者更加清晰地了解到产品中所含有的可能危害健康的化学物质，从而增强了产品的透明度和可信度。

消费者可以据此做出理性的购买选择，对于患有过敏等特殊情况的用户来说尤为重要。

2. 促进企业生产安全环保的产品CA Prop65标准的出台，促使企业更加注重产品质量和安全性。

为了避免因产品含有有害物质而受到法律的处罚和消费者的投诉，企业将更加谨慎地选择原材料和生产工艺，生产更加环保和安全的产品，有利于提升企业的社会形象和品牌价值。

加州第65号提案

加州第65号提案

加州第65号提案(一)加州第65号提案从颁布到现在已有20余年，一直秉持减少有毒化学物质的暴露的宗旨。

它允许加州居民通过一定的方式消除消费品和工业中的致癌物质和生殖毒性化学物质的行为。

自第65号提案制定以来，众多关于消费品中含有毒化学物质诉讼案在加州不断出现，从而引领整个美国一系列的限制标准的实施。

第65号提案，即《加州安全饮用水和有毒物执行法》，于1986 年11 月经加州居民投票，以压倒性的票数一致通过。

该提案由加州环境保护署(Cal/ EPA)辖下的环境健康危害评估机构(OEHHA) 执行。

提案规定，从事买卖的个体，其雇员人数达10个或10个以上的（另有豁免的除外），须在含已获知可致癌或生殖毒性的化学物质的产品上贴上清晰﹑合理的警告标签，以避免与人体接触，且不得将该等化学物质排放到饮用水中。

消费品警告可直接置于产品标签上，也可置于店面产品附近的显眼处（参照表1）。

表1 警告标签典型示例警告示例1 2WARNING: This product contains a chemical known to the State of California to cause cancer WARNING: This product contains a chemical known to the State ofCalifornia to cause birth defects or other reproductive harm第65号提案列出了大约800种已被加州当局确定为致癌性或生殖毒性的化学物清单。

该类化学物质清单包括大量自然产生的和人工合成的化学物质，包括用于杀虫剂﹑普通家用产品﹑食品﹑药物﹑染料或溶剂的添加剂或配料。

它们可用于制造业和建造业，也可以是化学过程的副产品，如机动车尾气。

所列化学物质包括烟草烟雾﹑金属（例如：铅﹑镉和镍）和有机化学物质（例如邻苯二甲酸盐：BBP﹑DBP﹑DEHP﹑DIDP﹑DnHP等，及多环芳香烃：苯并芘等）。

ca65认证内容

ca65认证内容

ca65认证内容
CA65认证是加州65号法案（California Proposition 65）的认证，该法
案全称为《毒物清除法案》（Safe Drinking Water and Toxic Enforcement Act of 1986），旨在保护公众免受能够引发致癌、生殖毒性、生育毒性或其他危害健康的化学物质的危害。

根据该法案的规定，加州政府负责公布一份名为“加州65号清单”（Proposition 65 List）的化学物质清单，其中包括被认定为对人体健康有潜在危害的化学物质。

这份清单是动态更新的，随着新的研究和评估结果的出现，新的化学物质可能被添加到清单中。

根据加州65号法案的要求，对于包含清单中化学物质的产品，制造商、分
销商和零售商需要在产品上提供警示标签或以其他方式向消费者提供有关该化学物质的风险信息。

这样，消费者可以在购买和使用产品时知晓其中可能存在的潜在风险。

CA65认证的管控内容包含：
1. 检测产品上每种材质的邻苯二甲酸盐含量和总铅含量。

2. 管控的物质种类比较多，设计的产品范围包含珠宝、纺织服装、玩具以及电子电器类。

3. 杜绝饮用水源污染，任何企业不得有意排放或释放致癌性物质或有生殖毒性物质进入水源或可能污染到水源的土地中。

4. 对于加州65法规中列出的物质，需提供清晰合理的警告（除非暴露水平很低，不会构成风险）。

有毒物质暴露大于管控水平时，企业需提供加州
65警示。

当某一种化学物质被列入法规清单，需在一年内完成警告的执行，20个月内终止化学物质排放至饮用水源头。

如需了解更多关于CA65认证的内容，建议咨询相关专业人员获取帮助。

p65法案

p65法案

p65法案
P65法案是指加利福尼亚州的一项法案，全名为加利福尼亚州议会提案65号法案（California Proposition 65）。

该法案于1986年通过，旨在保护加利福尼亚州居民免受化学物质引起的健康危害。

根据P65法案，加利福尼亚州政府要求企业在其产品中包含可能对人体健康产生危害的化学物质时，必须在产品上标注警告。

这些化学物质包括被国际机构确定为致癌物质、生殖毒性物质或导致先天缺陷的物质。

该法案要求在销售、分销或提供商品时提供警告，并对违反该要求的企业进行罚款。

此外，该法案还规定了民事诉讼程序，允许个人或组织对违反法案的企业提起诉讼，以保护消费者权益。

P65法案在加利福尼亚州引起了广泛的争议。

一方面，该法案提供了消费者对潜在健康风险的信息，使其能够做出知情的购买决策。

另一方面，一些人认为该法案存在滥用的可能性，导致大量的警告标签出现在各种商品上，使消费者对真正的风险产生麻木感。

总的来说，P65法案是加利福尼亚州对化学物质危害的一项法律规定，旨在保护消费者的健康和权益。

加州65最新案例介绍

加州65最新案例介绍
注：原“children’s vinyl bag”, “children’s bag with vinyl zipper pull”的DEHP测试取 消。
Bags: Lunch bag and lunch boxes (soft) 箱包：午餐包和午餐盒（软材料）
☆Case No. : SF-475982 ☆案例号：SF-475982
z z
Paints or other surface coatings ≤0.009 % (90ppm) 油漆或其它表面涂层≤0.009 % (90ppm)
• PVC component ≤0.02 % (200ppm) PVC部件≤0.02 % (200ppm)
z
z
• Leather including composited leather ≤0.03 % (300ppm) 皮革（包括合成皮革）≤0.03 % (300ppm)
2. California Proposition 65最新案例
Artificial turf products 人造草皮产品
☆Case No. : RG-400091 ☆案例号：RG-400091
Requirement: Lead (Method: EPA 3050B/3051): 要求：铅含量 (方法：EPA 3050B/3051): Each accessible component ≤0.005 % (50ppm) 每一可接触的部件≤0.005 % (50ppm)
☆Case No. :RG-399102 ☆案例号：RG-399102
Requirement: Lead (Method: EPA 3050B/3051): 要求：铅含量 (方法：EPA 3050B/3051):

加州65号提案普洱

加州65号提案普洱

加州65号提案普洱一、背景介绍普洱茶是一种中国传统的发酵茶，以其独特的香气和健康益处而闻名于世。

然而，在加州，普洱茶的销售和使用受到了一些限制。

加州65号提案是一项针对普洱茶的法案，旨在解除这些限制并促进普洱茶的发展和消费。

二、加州65号提案的内容加州65号提案主要包括以下几个方面的内容：1. 普洱茶的合法化该提案旨在将普洱茶列为合法的茶叶种类之一，解除对普洱茶销售和使用的限制。

这意味着普洱茶可以在加州合法销售和消费，而不再受到特殊的管制。

2. 普洱茶的质量监管为了保证消费者的权益，该提案还规定了普洱茶的质量监管标准。

普洱茶生产商和销售商需要遵守相关的质量监管要求，确保所售普洱茶的质量和安全。

3. 普洱茶的推广和宣传该提案鼓励普洱茶的推广和宣传活动，以增加消费者对普洱茶的认识和了解。

这可以通过组织普洱茶文化节、举办普洱茶品鉴会等方式来实现，提高普洱茶在加州的知名度和市场份额。

三、加州65号提案的意义加州65号提案的通过和实施对普洱茶的发展和消费将产生以下几个重要的影响：1. 促进普洱茶市场的繁荣普洱茶作为一种传统的中国茶叶，在加州市场上一直受到限制，这限制了普洱茶的销售和消费。

通过解除限制，普洱茶可以在加州市场上得到更多的推广和销售，进而促进普洱茶市场的繁荣。

2. 丰富消费者的选择加州65号提案的通过将使得消费者可以更方便地购买到普洱茶，丰富了茶叶市场的选择。

普洱茶以其独特的风味和健康益处吸引着越来越多的消费者，通过加州65号提案，消费者可以更好地享受到普洱茶带来的美味和健康。

3. 推动中美茶文化的交流普洱茶作为中国传统的茶叶，其文化和历史背景深厚。

通过加州65号提案的通过和实施，可以促进中美茶文化的交流和互动。

加州市场的普洱茶销售将吸引更多的中国茶文化爱好者和专家来到加州，与当地的茶文化爱好者进行交流和合作，推动中美茶文化的融合和发展。

四、结论加州65号提案的通过将对普洱茶的发展和消费产生积极的影响。

加州第65号提案 英文官方说明

加州第65号提案 英文官方说明

Proposition 65 in Plain LanguageWhat is Proposition 65?In 1986, California voters approved an initiative to address their growing concerns about exposure to toxic chemicals. That initiative became the Safe Drinking Water and Toxic Enforcement Act of 1986, better known by its original name of Proposition 65.Proposition 65 requires the State to publish a list of chemicals known to cause cancer or birth defects or other reproductive harm. This list, which must be updated at least oncea year, has grown to include over 800 chemicals since it was first published in 1987. Proposition 65 requires businesses to notify Californians about significant amounts of chemicals in the products they purchase, in their homes or workplaces, or that arereleased into the environment. By providing this information, Proposition 65 enables Californians to make informed decisions about protecting themselves from exposure tothese chemicals. Proposition 65 also prohibits California businesses from knowingly discharging significant amounts of listed chemicals into sources of drinking water.The Office of Environmental Health Hazard Assessment (OEHHA) administers the Proposition 65 program. OEHHA, which is part of the California EnvironmentalProtection Agency (Cal/EPA), also evaluates all currently available scientific informationon substances considered for placement on the Proposition 65 list.What types of chemicals are on the Proposition 65 list?The list contains a wide range of naturally occurring and synthetic chemicals that areknown to cause cancer or birth defects or other reproductive harm. These chemicalsinclude additives or ingredients in pesticides, common household products, food, drugs, dyes, or solvents. Listed chemicals may also be used in manufacturing andconstruction, or they may be byproducts of chemical processes, such as motor vehicle exhaust.How is a chemical added to the list?There are four principal ways for a chemical to be added to the Proposition 65 list. A chemical can be listed if either of two independent committees of scientists and health professionals finds that the chemical has been clearly shown to cause cancer or birth defects or other reproductive harm. These two committees—the CarcinogenIdentification Committee (CIC) and the Developmental and Reproductive Toxicant (DART) Identification Committee—are part of OEHHA’s Science Advisory Board. Thecommittee members are appointed by the Governor and are designated as the “State’s Qualified Experts” for evaluating chemicals under Proposition 65. When determining whether a chemical should be placed on the list, the committees base their decisions on the most current scientific information available. OEHHA staff scientists compile all relevant scientific evidence on various chemicals for the committees to review. The committees also consider comments from the public before making their decisions.A second way for a chemical to be listed is if an organization designated as an "authoritative body" by the CIC or DART Identification Committee has identified it as causing cancer or birth defects or other reproductive harm. The following organizations have been designated as authoritative bodies: the U.S. Environmental Protection Agency, U.S. Food and Drug Administration (U.S. FDA), National Institute for Occupational Safety and Health, National Toxicology Program, and International Agency for Research on Cancer.A third way for a chemical to be listed is if an agency of the state or federal government requires that it be labeled or identified as causing cancer or birth defects or other reproductive harm. Most chemicals listed in this manner are prescription drugs that are required by the U.S. FDA to contain warnings relating to cancer or birth defects or other reproductive harm.A fourth way requires the listing of chemicals meeting certain scientific criteria and identified in the California Labor Code as causing cancer or birth defects or other reproductive harm. This method established the initial chemical list following voter approval of Proposition 65 in 1986 and continues to be used as a basis for listing as appropriate.What requirements does Proposition 65 place on companies doing business in California?Businesses are required to provide a "clear and reasonable" warning before knowingly and intentionally exposing anyone to a listed chemical. This warning can be given by a variety of means, such as by labeling a consumer product, posting signs at the workplace, distributing notices at a rental housing complex, or publishing notices in a newspaper. Once a chemical is listed, businesses have 12 months to comply with warning requirements.Proposition 65 also prohibits companies that do business within California from knowingly discharging listed chemicals into sources of drinking water. Once a chemical is listed, businesses have 20 months to comply with the discharge prohibition. Businesses with less than 10 employees and government agencies are exempt from Proposition 65’s warning requirements and prohibition on discharges into drinking water sources. Businesses are also exempt from the warning requirement and discharge prohibition if the exposures they cause are so low as to create no significant risk of cancer or birth defects or other reproductive harm. Health risks are explained in more detail below.What does a warning mean?If a warning is placed on a product label or posted or distributed at the workplace, a business, or in rental housing, the business issuing the warning is aware or believesthat one or more listed chemicals is present. By law, a warning must be given for listed chemicals unless exposure is low enough to pose no significant risk of cancer or is significantly below levels observed to cause birth defects or other reproductive harm. For chemicals that are listed as causing cancer, the "no significant risk level” is defined as the level of exposure that would result in not more than one excess case of cancer in 100,000 individuals exposed to the chemical over a 70-year lifetime. In other words, a person exposed to the chemical at the “no significant risk level” for 70 years would not have more than a “one in 100,000” chance of developing cancer as a result of that exposure.For chemicals that are listed as causing birth defects or reproductive harm, the “no observable effect level” is determined by identifying the level of exposure that has been shown to not pose any harm to humans or laboratory animals. Proposition 65 then requires this “no observable effect level” to be divided by 1,000 in order to provide an ample margin of safety. Businesses subject to Proposition 65 are required to provide a warning if they cause exposures to chemicals listed as causing birth defects or reproductive harm that exceed 1/1000th of the “no observable effect level.”To further assist businesses, OEHHA develops numerical guidance levels, known as “safe harbor numbers” (described below) for determining whether a warning is necessary or whether discharges of a chemical into drinking water sources are prohibited. However, a business may choose to provide a warning simply based on its knowledge, or assumption, about the presence of a listed chemical without attempting to evaluate the levels of exposure. Because businesses do not file reports with OEHHA regarding what warnings they have issued and why, OEHHA is not able to provide further information about any particular warning. The business issuing the warning should be contacted for specific information, such as what chemicals are present, and at what levels, as well as how exposure to them may occur.What are safe harbor levels?As stated above, to guide businesses in determining whether a warning is necessary or whether discharges of a chemical into drinking water sources are prohibited, OEHHA has developed safe harbor levels. A business has “safe harbor” from Proposition 65 warning requirements or discharge prohibitions if exposure to a chemical occurs at or below these levels. These safe harbor levels consist of No Significant Risk Levels for chemicals listed as causing cancer and Maximum Allowable Dose Levels for chemicals listed as causing birth defects or other reproductive harm. OEHHA has established over 300 safe harbor levels to date and continues to develop more levels for listed chemicals.What if there is no safe harbor level?If there is no safe harbor level for a chemical, businesses that expose individuals to that chemical would be required to provide a Proposition 65 warning, unless the business can show that the anticipated exposure level will not pose a significant risk of cancer or reproductive harm. OEHHA has adopted regulations that provide guidance for calculating a level in the absence of a safe harbor level. Regulations are available atArticle 7 and Article 8 of Title 27, California Code of Regulations. Determining anticipated levels of exposure to listed chemicals can be very complex. Although a business has the burden of proving a warning is not required, a business is discouraged from providing a warning that is not necessary and instead should consider consulting a qualified professional if it believes an exposure to a listed chemical may not require a Proposition 65 warning.Who enforces Proposition 65?The California Attorney General’s Office enforces Proposition 65. Any district attorney or city attorney (for cities whose population exceeds 750,000) may also enforce Proposition 65. In addition, any individual acting in the public interest may enforce Proposition 65 by filing a lawsuit against a business alleged to be in violation of this law. Lawsuits have been filed by the Attorney General’s Office, district attorneys, consumer advocacy groups, and private citizens and law firms. Penalties for violatingProposition 65 by failing to provide notices can be as high as $2,500 per violation per day.How is Proposition 65 meeting its goal of reducing exposure to hazardous chemicals in California?Since it was passed in 1986, Proposition 65 has provided Californians with information they can use to reduce their exposures to listed chemicals that may not have been adequately controlled under other State or federal laws. This law has also increased public awareness about the adverse effects of exposures to listed chemicals. For example, Proposition 65 has resulted in greater awareness of the dangers of alcoholic beverage consumption during pregnancy. Alcohol consumption warnings are perhaps the most visible health warnings issued as a result of Proposition 65.Proposition 65’s warning requirement has provided an incentive for manufacturers to remove listed chemicals from their products. For example, trichloroethylene, which causes cancer, is no longer used in most correction fluids; reformulated paint strippers do not contain the carcinogen methylene chloride; and toluene, which causes birth defects or other reproductive harm, has been removed from many nail care products. In addition, a Proposition 65 enforcement action prompted manufacturers to decrease the lead content in ceramic tableware and wineries to eliminate the use of lead-containing foil caps on wine bottles.Proposition 65 has also succeeded in spurring significant reductions in California of air emissions of listed chemicals, such as ethylene oxide, hexavalent chromium, and chloroform.Although Proposition 65 has benefited Californians, it has come at a cost for companies doing business in the state. They have incurred expenses to test products, develop alternatives to listed chemicals, reduce discharges, provide warnings, and otherwise comply with this law. Recognizing that compliance with Proposition 65 comes at a price, OEHHA is working to make the law’s regulatory requirements as clear as possible and ensure that chemicals are listed in accordance with rigorous science in an open public process.Where can I get more information on Proposition 65?For general information on the Proposition 65 list of chemicals, you may contact OEHHA’s Proposition 65 program at (916) 445-6900, or visit/prop65.html . For enforcement information, contact the California Attorney General’s Office at (510) 873-6321, or visit /prop65.Updated February 2013。

加州65提案物质管控清单-概述说明以及解释

加州65提案物质管控清单-概述说明以及解释

加州65提案物质管控清单-概述说明以及解释1.引言1.1 概述加州65提案，全名为加州65号公告，是由加州议会提出的一项法案，旨在对危险化学物质进行控制和管理。

该提案制定了一个物质管控清单，列出了一系列被认为有潜在危害的物质，要求企业在产品中使用这些物质时进行披露和警示。

这个清单不仅包括化学品，还涉及到了化妆品、食品和家庭用品等不同领域的产品。

加州65提案的目的是保护公众和环境的健康与安全，增加对潜在危害物质的认识和警惕。

通过公开披露和警示，消费者可以更好地了解产品中存在的潜在风险，并自主选择是否购买或使用。

该提案的实施对企业产生了重大影响，要求企业进行复杂的风险评估和物质管理，以确保产品的安全性和合规性。

同时，这项法案也促使了企业加强研发和创新，寻找替代品和更安全的生产工艺，以适应市场的需求和法规的要求。

经过多年的实施和不断调整，加州65提案已经成为全国范围内关于危险化学物质管理的重要准则。

许多其他州和国家也参考加州65提案的物质管控清单，加强对潜在危险物质的监管和管理。

本文将深入探讨加州65提案的内容和重要性，分析其对社会和环境的影响，以及对企业和消费者的意义。

通过对加州65提案的全面了解，我们能够更好地理解物质管控的重要性，促进可持续发展和环境保护。

1.2文章结构文章结构部分的内容可以参考以下写法：1.2 文章结构本文将按照以下结构进行讨论：第二章将介绍加州65提案的背景和内容。

首先，我们将简要回顾提案的起因和背景，以了解为什么有必要进行物质管控。

接下来，我们将详细探讨加州65提案的具体内容，包括提案中列出的物质管控清单及其所涵盖的范围。

第三章将探讨物质管控清单的重要性。

我们将分析为什么对这些物质进行管控是至关重要的，以及物质管控对于保护人类和环境健康的积极意义。

我们还将讨论这些清单对于企业和消费者的影响，并探讨可能的挑战和解决方案。

最后，第四章将从整体上总结加州65提案的影响并探讨其在社会和环境方面的意义。

california proposition 65列表

california proposition 65列表

california proposition 65列表加州65号提案（California Proposition 65）是加利福尼亚州的一项法律要求，旨在提供有关在该州存在的可能导致癌症或生殖毒性的化学物质的信息。

该提案要求加州政府维护一份名为“有害物质清单”（List of Chemicals Known to the State of California to Cause Cancer or Reproductive Toxicity）的列表，其中包含已知的可能有害的化学物质。

根据加州65号提案，以下是一些常见的化学物质，可能会出现在该有害物质清单中。

请注意，这仅是一些示例，并不代表完整的清单：1. 苯（Benzene）2. 铅（Lead）3. 汞（Mercury）4. 镉（Cadmium）5. 苯并芘（Benzo[a]pyrene）6. 甲醛（Formaldehyde）7. 砷（Arsenic）8. 乙醛（Acetaldehyde）9. 可塑剂（Phthalates）10. 镍（Nickel）这些化学物质可能存在于许多不同的产品和环境中，包括食品、饮用水、药物、化妆品、家具、建筑材料等。

根据加州65号提案的规定，如果产品中含有该有害物质清单中的任何一种化学物质，制造商、分销商或零售商需要提供警告，以使消费者能够知晓潜在的危险。

请注意，有害物质清单是根据科学研究和相关机构的评估编制的，并且可能会定期更新。

如果您需要最新的有害物质清单信息，建议查阅加利福尼亚州环境保护局（California Environmental Protection Agency）或加利福尼亚州劳工部（California Department of Labor）的官方网站，以获取最新的清单和相关信息。

加州65铅豁免条款

加州65铅豁免条款

加州65铅豁免条款加利福尼亚的“65铅豁免”指的是对于某些特定的产品，可以不遵守加州的有毒有害化学物质通报法案（也就是California Proposition 65）。

这些产品一般都是铅含量高的，而这项豁免措施被称为“65铅豁免”。

下面我们来看一下65铅豁免的一些背景和细节。

首先，我们需要明白，“有毒有害化学物质通报法案”是一项要求制造商、分销商和零售商在销售含有一定限量的“有毒有害物质”的产品时，必须贴上警示标签的法案。

这些化学物质包括致癌物质、生殖毒性化学品和先天性缺陷化学物质等。

这个法案于1986年通过，针对的是在加州销售的生产商的产品。

但是随着时间的推移，发现这项法案的应用范围非常广泛，几乎每个行业的产品都有可能含有被禁止的化学成分。

诸如钛酸酯等常见添加剂成为“有毒成分”的事情屡见不鲜。

因此，政府开放了一些豁免条款，允许某些产品不需要按照法案要求进行标记警示，而这其中就有“65铅豁免”。

那么，仅仅是铅含量达到一定数值就可以享受65铅豁免条款吗？事实并非如此。

65铅豁免是对含有铅的特定种类的产品所做出的例外规定。

被允许豁免包括不锈钢、黄铜、铁、镀层和涂料等一些化学成分复杂的产品。

同时，豁免标准由加州州环境保护署的毒理学员根据固定的标准进行审核和制定，根据不同的如材料类型、产品用途等来确定每种合格产品的铅含量上限。

这个过程非常繁琐，评估的时间长短取决于产品的类型和操作的复杂程度。

评估结果会公布在加州环保署的官方网站上，制造商可以通过网站查询自己生产的产品是否被允许享受豁免。

需要注意的是，65铅豁免并非永久有效，而是需要不断审核和更新。

在所有情况下，根据经济利益和公众健康安全的考虑，加州环境保护署都可以决定是否要取消某项豁免条款。

最后，需要指出的是，这个豁免框架并不是针对减轻产品中有害物质的含量的持续性解决方案，因为在大多数情况下，产品中的铅含量只是通过去除材料而减轻，而不是通过替代和创新出更安全的办法来解决。

美国加州65标准 ca 65

美国加州65标准 ca 65

美国加州65标准（CP65标准）内容资料及检测测试（第65号提案，即《加州安全饮用水和有毒物执行法》）加州第65号提案(一)加州第65号提案从颁布到现在已有20余年，一直秉持减少有毒化学物质的暴露的宗旨。

它允许加州居民通过一定的方式消除消费品和工业中的致癌物质和生殖毒性化学物质的行为。

自第65号提案制定以来，众多关于消费品中含有毒化学物质诉讼案在加州不断出现，从而引领整个美国一系列的限制标准的实施。

第65号提案，即《加州安全饮用水和有毒物执行法》，于1986 年11 月经加州居民投票，以压倒性的票数一致通过。

该提案由加州环境保护署(Cal/ EPA)辖下的环境健康危害评估机构(OEHHA) 执行。

提案规定，从事买卖的个体，其雇员人数达10个或10个以上的（另有豁免的除外），须在含已获知可致癌或生殖毒性的化学物质的产品上贴上清晰﹑合理的警告标签，以避免与人体接触，且不得将该等化学物质排放到饮用水中。

消费品警告可直接置于产品标签上，也可置于店面产品附近的显眼处（参照表1）。

表1 警告标签典型示例警告示例1 2WARNING: Thisproduct contains achemical known tothe StateofCalifornia to causecancer WARNING: This productcontains a chemicalknown to the State ofCalifornia to cause birthdefects or otherreproductive harm第65号提案列出了大约800种已被加州当局确定为致癌性或生殖毒性的化学物清单。

该类化学物质清单包括大量自然产生的和人工合成的化学物质，包括用于杀虫剂﹑普通家用产品﹑食品﹑药物﹑染料或溶剂的添加剂或配料。

它们可用于制造业和建造业，也可以是化学过程的副产品，如机动车尾气。

所列化学物质包括烟草烟雾﹑金属（例如：铅﹑镉和镍）和有机化学物质（例如邻苯二甲酸盐：BBP﹑DBP﹑DEHP﹑DIDP ﹑DnHP等，及多环芳香烃：苯并芘等）。

美国加州65号提案合规指南

美国加州65号提案合规指南

美国加州65号提案合规指南下载温馨提示：该文档是我店铺精心编制而成，希望大家下载以后，能够帮助大家解决实际的问题。

文档下载后可定制随意修改，请根据实际需要进行相应的调整和使用，谢谢!并且，本店铺为大家提供各种各样类型的实用资料，如教育随笔、日记赏析、句子摘抄、古诗大全、经典美文、话题作文、工作总结、词语解析、文案摘录、其他资料等等，如想了解不同资料格式和写法，敬请关注!Download tips: This document is carefully compiled by the editor. I hope that after you download them, they can help yousolve practical problems. The document can be customized and modified after downloading, please adjust and use it according to actual needs, thank you!In addition, our shop provides you with various types of practical materials, such as educational essays, diary appreciation, sentence excerpts, ancient poems, classic articles, topic composition, work summary, word parsing, copy excerpts,other materials and so on, want to know different data formats and writing methods, please pay attention!在当前数字化时代，随着信息的爆炸性增长，人们对个人数据隐私和信息安全的关注也日益增加。

加州65宣告书（中英文）

加州65宣告书（中英文）

加州65宣告书（中英文）California Proposition 65 Declaration加州65宣告書California's Safe Drinking Water and Toxic Enforcement Act of 1986 (known as "Prop 65"), seeks to ensure that individuals in California are informed about exposure to chemicals known by the State to cause cancer and/or reproductive harm. To comply, businesses are required to provide a clear and reasonable warning before exposing anyone to a listed chemical. In late 2016, the State of California amended the warning language and methods that are deemed "clear and reasonable" under the statute. These amendments become effective on August 30, 2018.加州1986年的“安全飲用水和有毒物質強制法案”(稱為“第65號提案”)，要求該州公佈已知會造成癌症、先天性缺陷及其它生殖傷害的化學物質清單。

為了遵守規定，企業必須在將任何人暴露於所列化學品之前能提供警告標示。

2016年底，美國加州OEHHA修改了根據法規被視為“明確和合理”的警告語言和方法，這些修正案於2018年8月30日生效。

This declaration is to inform XXX at products manufactured by (Company Name) do not contain chemicals which are listed on California’s Safe Drinking Water & Toxic Enforcement Act of 1986. This Act, commonly known as Proposition 65 (Prop 65), establishes a list of chemicals which the state of California’s risk assessment process has determined to present a risk of cancer, birth defects or other reproductive harm. 此宣告書在通知，(公司名稱) 生產的產品不含加州1986年安全飲用水和有毒執法法案中列出的化學品。

加州65号提案管理流程

加州65号提案管理流程

加州65号提案管理流程加州65号提案是指加州议会在2017年通过的一项法案，旨在规范和管理政府机构的流程和程序。

该提案的目的是为了提高政府机构的效率和透明度，确保公众对政府决策的参与和监督。

该提案主要包括以下几个方面的内容：一、流程和程序的规范化加州65号提案要求政府机构在决策和执行过程中必须遵守一系列规定的流程和程序。

这些规定涵盖了政府机构内部的决策程序、信息公开的要求、公众参与的机制等方面。

通过规范化流程和程序，可以确保政府机构的决策合法、合理，减少滥用职权和腐败现象的发生。

二、公众参与的推广加州65号提案要求政府机构在决策过程中必须积极推动公众的参与。

具体而言，政府机构需要在决策过程中向公众征求意见、听取建议，确保公众的声音被充分听取和考虑。

此外，政府机构还需要及时向公众公布决策的结果和理由，增加决策的透明度。

三、信息公开的要求加州65号提案要求政府机构必须主动公开相关的决策和执行信息。

这包括决策的依据、过程、结果等方面的信息。

政府机构需要通过官方网站、媒体等渠道向公众公开这些信息，确保公众对政府决策有全面的了解和监督。

四、责任追究的机制加州65号提案要求政府机构必须建立健全的责任追究机制。

如果政府机构在决策和执行过程中违反法律、滥用职权等，公众有权向相关机构提出投诉和申诉。

政府机构需要及时调查处理这些投诉和申诉，并对相关责任人进行追责。

这样可以确保政府机构的决策和行为合法、合规。

五、效率和透明度的提升加州65号提案的最终目标是提高政府机构的效率和透明度。

通过规范流程和程序、推动公众参与、加强信息公开和建立责任追究机制，可以减少决策的滞后和错误，提高政府机构的决策质量和执行效率。

同时，公众对政府决策的参与和监督也可以增加政府的透明度，减少腐败和滥用职权的可能性。

加州65号提案是一项旨在规范和管理政府机构流程的法案。

该提案通过规范流程和程序、推动公众参与、加强信息公开和建立责任追究机制等手段，旨在提高政府机构的效率和透明度。

  1. 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

STATE OF CALIFORNIAENVIRONMENTAL PROTECTION AGENCYOFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITYFEBRUARY 5, 2010The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and republish at least once per year the list of chemicals known to the State to cause cancer or reproductive toxicity. The identification number indicated in the following list is the ChemicalAbstracts Service (CAS) Registry Number. No CAS number is given when several substances are presented as a single listing. The date refers to the initial appearance of the chemical on the list. For easy reference, chemicals which are shown underlined are newly added. Chemicals or endpoints shown in strikeout were placed on the Proposition 65 list on the date noted, and have subsequently been removed.Chemical Type of Toxicity CAS No. Date Listed A-alpha-C (2-Amino-9H-pyrido [2,3-b]indole) cancer 26148-68-5 January 1, 1990 Acetaldehyde cancer 75-07-0 April 1, 1988 Acetamide cancer 60-35-5 January 1, 1990 Acetazolamide developmental 59-66-5 August 20, 1999 Acetochlor cancer 34256-82-1 January 1, 1989 Acetohydroxamic acid developmental 546-88-3 April 1, 1990 2-Acetylaminofluorene cancer 53-96-3 July 1, 1987 Acifluorfen sodium cancer 62476-59-9 January 1, 1990 Acrylamide cancer 79-06-1 January 1, 1990 Acrylonitrile cancer 107-13-1 July 1, 1987 Actinomycin D cancer 50-76-0 October 1, 1989 developmental October 1, 1992 AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)] acrylamide cancer 3688-53-7 July 1, 1987 Aflatoxins cancer --- January 1, 1988 Alachlor cancer 15972-60-8 January 1, 1989 Alcoholic beverages, when associatedwith alcohol abuse cancer --- July 1, 1988 Aldrin cancer 309-00-2 July 1, 1988 All-trans retinoic acid developmental 302-79-4 January 1, 1989 Allyl chloride Delisted October 29, 1999 cancer 107-05-1 January 1, 1990 Alprazolam developmental 28981-97-7 July 1, 1990 Altretamine developmental, male 645-05-6 August 20, 1999 Amantadine hydrochloride developmental 665-66-7 February 27, 2001 Amikacin sulfate developmental 39831-55-5 July 1, 1990 2-Aminoanthraquinone cancer 117-79-3 October 1, 1989 p -Aminoazobenzene cancer 60-09-3 January 1, 1990 o -Aminoazotoluene cancer 97-56-3 July 1, 19874-Aminobiphenyl (4-amino- diphenyl)cancer 92-67-1 February 27, 1987 1-Amino-2,4-dibromo- anthraquinonecancer 81-49-2 August 26, 1997 3-Amino-9-ethylcarbazole hydrochloride cancer 6109-97-3 July 1, 1989 2-Aminofluorene cancer153-78-6 January 29, 1999 Aminoglutethimide developmental 125-84-8 July 1, 1990 Aminoglycosidesdevelopmental ---October 1, 1992 1-Amino-2-methylanthraquinone cancer 82-28-0 October 1, 1989 2-Amino-5-(5-nitro-2-furyl)-1,3,4- thiadiazolecancer712-68-5 July 1, 1987 4-Amino-2-nitrophenol cancer119-34-6 January 29, 1999 Aminopterindevelopmental, female 54-62-6 July 1, 1987 Amiodarone hydrochloride developmental, female, male19774-82-4 August 26, 1997 Amitraz developmental 33089-61-1 March 30, 1999 Amitrole cancer61-82-5 July 1, 1987 Amoxapine developmental 14028-44-5 May 15, 1998 Amsacrinecancer51264-14-3 August 7, 2009tert-Amyl methyl ether developmental 994-05-8 December 18, 2009 Anabolic steroidsfemale, male --- April 1, 1990Analgesic mixtures containing phenacetincancer --- February 27, 1987 Angiotensin converting enzyme (ACE) inhibitors developmental --- October 1, 1992 Anilinecancer 62-53-3 January 1, 1990 Aniline hydrochloride cancer 142-04-1 May 15, 1998 o -Anisidinecancer 90-04-0 July 1, 1987 o -Anisidine hydrochloride cancer134-29-2 July 1, 1987 Anisindionedevelopmental 117-37-3 October 1, 1992 Antimony oxide (Antimony trioxide) cancer 1309-64-4 October 1, 1990 Anthraquinone cancer 84-65-1 September 28, 2007 Aramite cancer 140-57-8 July 1, 1987Areca nutcancer --- February 3, 2006 Aristolochic acidscancer --- July 9, 2004Arsenic (inorganic arsenic compounds)cancer-- February 27, 1987 Arsenic (inorganic oxides) developmental ---May 1, 1997Asbestoscancer1332-21-4 February 27, 1987 Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child orcomplications during delivery.) developmental, female50-78-2July 1, 1990Atenolol developmental 29122-68-7 August 26, 1997 Auramine cancer492-80-8 July 1, 1987Auranofin developmental 34031-32-8 January 29, 1999 Azacitidinecancer 320-67-2 January 1, 1992Azaserine cancer 115-02-6July 1, 1987Azathioprinecancerdevelopmental446-86-6 February 27, 1987 September 1, 1996 Azobenzene cancer 103-33-3 January 1, 1990Barbiturates developmental ---October 1, 1992 Beclomethasone dipropionate developmental 5534-09-8 May 15, 1998 Benomyl developmental, male 17804-35-2 July 1, 1991 Benthiavalicarb-isopropyl cancer 177406-68-7 July 1, 2008 Benz[a]anthracene cancer 56-55-3 July 1, 1987Benzene cancerdevelopmental, male71-43-2 February 27, 1987 December 26, 1997 Benzidine [and its salts] cancer 92-87-5 February 27, 1987 Benzidine-based dyes cancer --- October 1, 1992 Benzodiazepines developmental ---October 1, 1992 Benzo[b]fluoranthene cancer 205-99-2 July 1, 1987 Benzo[j]fluoranthene cancer 205-82-3 July 1, 1987 Benzo[k]fluoranthene cancer 207-08-9 July 1, 1987 Benzofuran cancer 271-89-6 October 1, 1990 Benzo[a]pyrene cancer 50-32-8 July 1, 1987 Benzotrichloride cancer 98-07-7 July 1, 1987 Benzphetamine hydrochloride developmental 5411-22-3 April 1, 1990 Benzyl chloride cancer 100-44-7 January 1, 1990 Benzyl violet 4B cancer 1694-09-3 July 1, 1987 Beryllium and beryllium compounds cancer --- October 1, 1987 Betel quid with tobacco cancer --- January 1, 1990 Betel quid without tobacco cancer ---February 3, 2006 2,2-Bis(bromomethyl)-1,3- propanediolcancer 3296-90-0 May 1, 1996 Bis(2-chloroethyl)ether cancer 111-44-4 April 1, 1988N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine)cancer494-03-1 February 27, 1987 Bischloroethyl nitrosourea (BCNU) (Carmustine) cancer developmental 154-93-8 July 1, 1987 July 1, 1990Bis(chloromethyl)ether cancer542-88-1 February 27, 1987 Bis(2-chloro-1-methylethyl)ether,technical gradecancer --- October 29, 1999 Bitumens, extracts of steam-refined and air refined cancer ---January 1, 1990 Bracken fern cancer ---January 1, 1990 Bromacil lithium salt developmentalmale53404-19-6 May 18, 1999 January 17, 2003 Bromate cancer 15541-45-4 May 31, 2002 Bromodichloromethane cancer 75-27-4 January 1, 1990 Bromoethane cancer 74-96-4 December 22, 2000 Bromoform cancer 75-25-2 April 1, 19911-Bromopropane (1-BP) developmental, female,male106-94-5 December 7, 2004 2-Bromopropane (2-BP) female, male 75-26-3 May 31, 2005 Bromoxynil developmental 1689-84-5 October 1, 1990 Bromoxynil octanoate developmental1689-99-2May 18, 1999Butabarbital sodium developmental 143-81-7 October 1, 1992 1,3-Butadiene cancer106-99-0 April 1, 1988 1,3-Butadienedevelopmental, female, male 106-99-0 April 16, 2004 1,4-Butanediol dimethanesulfonate (Busulfan)cancerdevelopmental 55-98-1 February 27, 1987 January 1, 1989 Butylated hydroxyanisole cancer25013-16-5 January 1, 1990 Butyl benzyl phthalate (BBP) developmental 85-68-7 December 2, 2005 n-Butyl glycidyl ether male 2426-08-6 August 7, 2009 beta-Butyrolactone cancer 3068-88-0 July 1, 1987Cacodylic acid cancer75-60-5 May 1, 1996 Cadmiumdevelopmental, male --- May 1, 1997 Cadmium and cadmium compounds cancer--- October 1, 1987 Caffeic acid cancer 331-39-5 October 1, 1994 Captafol cancer 2425-06-1 October 1, 1988 Captancancer133-06-2 January 1, 1990 Carbamazepine developmental 298-46-4 January 29, 1999 Carbaryl cancer63-25-2 February 5, 2010 Carbaryl developmental, male 63-25-2 August 7, 2009 Carbazolecancer 86-74-8 May 1, 1996Carbon black (airborne, unbound particles of respirable size) cancer1333-86-4 February 21, 2003 Carbon disulfidedevelopmental, female, male75-15-0 July 1, 1989 Carbon monoxide developmental 630-08-0 July 1, 1989 Carbon tetrachloride cancer 56-23-5 October 1, 1987 Carbon-black extracts cancer---January 1, 1990 Carboplatindevelopmental 41575-94-4 July 1, 1990N-Carboxymethyl-N-nitrosourea cancer 60391-92-6 January 25, 2002 Catecholcancer 120-80-9 July 15, 2003 Ceramic fibers (airborne particles of respirable size)cancer --- July 1, 1990 Certain combined chemotherapy for lymphomas cancer --- February 27, 1987 Chenodiol developmental 474-25-9 April 1, 1990Chlorambucilcancerdevelopmental 305-03-3 February 27, 1987 January 1, 1989 Chloramphenicolcancer56-75-7 October 1, 1989 Chlorcyclizine hydrochloride developmental 1620-21-9 July 1, 1987 Chlordanecancer 57-74-9 July 1, 1988 Chlordecone (Kepone) cancerdevelopmental 143-50-0 January 1, 1988 January 1, 1989 Chlordiazepoxidedevelopmental 58-25-3 January 1, 1992 Chlordiazepoxide hydrochloride developmental 438-41-5 January 1, 1992 Chlordimeform cancer 6164-98-3 January 1, 1989 Chlorendic acidcancer 115-28-6 July 1, 1989 Chlorinated paraffins (Average Chain length, C12; ap- proximately 60 percent chlorine by weight)cancer108171-26-2July 1, 1989p -Chloroanilinecancer 106-47-8 October 1, 1994 p -Chloroaniline hydrochloride cancer 20265-96-7 May 15, 1998 Chlorodibromomethane Delisted October 29, 1999 cancer 124-48-1 January 1, 1990 Chloroethane (Ethyl chloride) cancer 75-00-3 July 1, 1990 1-(2-Chloroethyl)-3-cyclohexyl- 1-nitrosourea (CCNU) (Lomustine)cancerdevelopmental 13010-47-4 January 1, 1988 July 1, 1990 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) cancer 13909-09-6 October 1, 1988 Chloroform cancer67-66-3 October 1, 1987 Chloroformdevelopmental 67-66-3 August 7, 2009 Chloromethyl methyl ether (technical grade)cancer 107-30-2 February 27, 1987 3-Chloro-2-methylpropene cancer 563-47-3 July 1, 19891-Chloro-4-nitrobenzenecancer 100-00-5 October 29, 1999 4-Chloro-o -phenylenediamine cancer 95-83-0 January 1, 1988 Chloroprenecancer 126-99-8 June 2, 2000 2-Chloropropionic acid male 598-78-7 August 7, 2009 Chlorothalonilcancer 1897-45-6 January 1, 1989 p -Chloro-o -toluidinecancer 95-69-2 January 1, 1990 p-Chloro-o -toluidine, strong acid salts ofcancer --- May 15, 1998 5-Chloro-o -toluidine and its strong acid salts cancer---October 24, 1997 Chlorotrianisene cancer 569-57-3 September 1, 1996 Chlorozotocin cancer54749-90-5 January 1, 1992 Chlorsulfurondevelopmental, female, male64902-72-3 May 14, 1999 Chromium (hexavalent compounds) cancer--- February 27, 1987 Chromium (hexavalent compounds) developmental female,male--- December 19, 2008 Chrysene cancer 218-01-9 January 1, 1990 C.I. Acid Red 114 cancer 6459-94-5 July 1, 1992 C.I. Basic Red 9 monohydrochloride cancer 569-61-9 July 1, 1989 C.I. Direct Blue 15 cancer 2429-74-5 August 26, 1997 C.I. Direct Blue 218 cancer 28407-37-6 August 26, 1997 C.I. Solvent Yellow 14 cancer 842-07-9 May 15, 1998 Ciclosporin (Cyclosporin A; Cyclosporine) cancer 59865-13-3 79217-60-0 January 1, 1992 Cidofovir cancer, developmental,female, male113852-37-2 January 29, 1999 Cinnamyl anthranilate cancer 87-29-6 July 1, 1989 Cisplatin cancer 15663-27-1 October 1, 1988 Citrus Red No. 2 cancer 6358-53-8 October 1, 1989 Cladribine developmental 4291-63-8 September 1, 1996 Clarithromycin developmental 81103-11-9 May 1, 1997 Clobetasol propionate developmental, female 25122-46-7 May 15, 1998Clofibrate cancer 637-07-0 September 1, 1996 Clomiphene citrate developmental 50-41-9 April 1, 1990 Clorazepate dipotassium developmental57109-90-7October 1, 1992Cobalt metal powder cancer 7440-48-4 July 1, 1992 Cobalt [II] oxide cancer 1307-96-6 July 1, 1992 Cobalt sulfatecancer 10124-43-3 May 20, 2005 Cobalt sulfate heptahydrate cancer10026-24-1 June 2, 2000 Cocainedevelopmental, female 50-36-2 July 1, 1989 Codeine phosphate developmental 52-28-8 May 15, 1998Coke oven emissions cancer---February 27, 1987 Colchicinedevelopmental, male 64-86-8 October 1, 1992 Conjugated estrogenscancerdevelopmental ---February 27, 1987 April 1, 1990 Creosotes cancer ---October 1, 1988 p -Cresidine cancer 120-71-8 January 1, 1988 Cupferron cancer135-20-6 January 1, 1988 Cyanazine developmental 21725-46-2 April 1, 1990 Cycasin cancer14901-08-7 January 1, 1988 Cycloatedevelopmental 1134-23-2 March 19, 1999 Cyclohexanol Delisted January 25, 2002 male108-93-0 November 6, 1998 Cycloheximidedevelopmental 66-81-9 January 1, 1989 Cyclophosphamide (anhydrous) cancerdevelopmental, female, male 50-18-0 February 27, 1987 January 1, 1989 Cyclophosphamide (hydrated) cancerdevelopmental, female, male6055-19-2 February 27, 1987 January 1, 1989 Cyhexatin developmental 13121-70-5 January 1, 1989 Cytarabine developmental 147-94-4 January 1, 1989 Cytembena cancer 21739-91-3 May 15, 1998D&C Orange No. 17 cancer 3468-63-1 July 1, 1990 D&C Red No. 8 cancer 2092-56-0 October 1, 1990 D&C Red No. 9 cancer 5160-02-1 July 1, 1990 D&C Red No. 19 cancer 81-88-9 July 1, 1990 Dacarbazinecancerdevelopmental 4342-03-4 January 1, 1988 January 29, 1999 Daminozide cancer1596-84-5 January 1, 1990 Danazoldevelopmental 17230-88-5 April 1, 1990 Dantron (Chrysazin; 1,8- Dihydroxy-anthraquinone) cancer117-10-2 January 1, 1992 Daunomycincancer20830-81-3 January 1, 1988 Daunorubicin hydrochloride developmental23541-50-6 July 1, 1990 2,4-D butyric aciddevelopmental, male 94-82-6 June 18, 1999 DDD (Dichlorodiphenyl- dichloroethane) cancer 72-54-8 January 1, 1989 DDE (Dichlorodi-phenyldichloroethylene) cancer 72-55-9 January 1, 1989 DDT (Dichlorodi-phenyltrichloroethane) cancer50-29-3 October 1 , 1987 o,p’-DDT developmental, female, male789-02-6 May 15, 1998 p,p’-DDTdevelopmental, female, male50-29-3May 15, 1998DDVP (Dichlorvos) cancer62-73-7 January 1, 1989 2,4-DP (dichloroprop)Delisted January 25, 2002 developmental 120-36-5 April 27, 1999 N,N’-Diacetylbenzidine cancer 613-35-4 October 1, 1989 2,4-Diaminoanisolecancer 615-05-4 October 1, 1990 2,4-Diaminoanisole sulfate cancer 39156-41-7 January 1, 1988 4,4’-Diaminodiphenyl ether (4,4’-Oxydianiline) cancer 101-80-4 January 1, 1988 2,4-Diaminotoluenecancer95-80-7 January 1, 1988 Demeclocycline hydrochloride (internal use)developmental 64-73-3 January 1, 1992 Diaminotoluene (mixed) cancer---January 1, 1990 Diazepamdevelopmental 439-14-5 January 1, 1992 Diazoaminobenzene cancer136-35-6 May 20, 2005Diazoxidedevelopmental 364-98-7 February 27, 2001 Dibenz[a,h]acridine cancer 226-36-8 January 1, 1988 Dibenz[a,j]acridine cancer 224-42-0 January 1, 1988 Dibenz[a,h]anthracene cancer 53-70-3 January 1, 1988 7H-Dibenzo[c,g]carbazole cancer 194-59-2 January 1, 1988 Dibenzo[a,e]pyrene cancer 192-65-4 January 1, 1988 Dibenzo[a,h]pyrene cancer 189-64-0 January 1, 1988 Dibenzo[a,i]pyrene cancer 189-55-9 January 1, 1988 Dibenzo[a,l]pyrene cancer 191-30-0 January 1, 1988 Dibromoacetic acidcancer 631-64-1 June 17, 2008 1,2-Dibromo-3-chloropropane (DBCP)cancer male 96-12-8 July 1, 1987February 27, 1987 2,3-Dibromo-1-propanol cancer 96-13-9 October 1, 1994 Dichloroacetic acid cancer 79-43-6 May 1, 1996 Dichloroacetic acid male 79-43-6 August 7, 2009 p -Dichlorobenzene cancer 106-46-7 January 1, 1989 3,3’-Dichlorobenzidine cancer 91-94-1 October 1, 1987 3,3’-Dichlorobenzidine dihydrochloridecancer 612-83-9 May 15, 1998 1,4-Dichloro-2-butenecancer 764-41-0 January 1, 1990 3,3’-Dichloro-4,4’-diaminodiphenyl ethercancer 28434-86-8 January 1, 1988 1,1-Dichloroethanecancer 75-34-3 January 1, 1990 Dichloromethane (Methylene chloride) cancer75-09-2 April 1, 1988 Dichlorophene developmental 97-23-4 April 27, 1999 Dichlorphenamide developmental 120-97-8 February 27, 2001 Diclofop methyldevelopmental 51338-27-3 March 5, 1999 1,2-Dichloropropane cancer 78-87-5 January 1, 1990 1,3-Dichloropropene cancer542-75-6 January 1, 1989 Dicumarol developmental 66-76-2 October 1, 1992 Dieldrin cancer 60-57-1 July 1, 1988 Dienestrolcancer 84-17-3 January 1, 1990 Diepoxybutanecancer 1464-53-5 January 1, 1988 Diesel engine exhaustcancer ---October 1, 1990 Di(2-ethylhexyl)phthalate (DEHP) cancerdevelopmental, male 117-81-7 January 1, 1988 October 24, 2003 1,2-Diethylhydrazinecancer1615-80-1January 1, 1988Diethylstilbestrol (DES)cancerdevelopmental 56-53-1 February 27, 1987 July 1, 1987 Diethyl sulfate cancer64-67-5 January 1, 1988 Diflunisaldevelopmental, female 22494-42-4 January 29, 1999 Diglycidyl ethermale 2238-07-5 August 7, 2009 Diglycidyl resorcinol ether (DGRE) cancer101-90-6 July 1, 1989 Dihydroergotamine mesylate developmental 6190-39-2 May 1, 1997 Dihydrosafrolecancer94-58-6 January 1, 1988 Di-n -butyl phthalate (DBP) developmental, female, male84-74-2 December 2, 2005 Di-n -hexyl phthalate (DnHP) female, male 84-75-3 December 2, 2005 Di-isodecyl phthalate (DIDP) developmental 68515-49-1/ 26761-40-0 April 20, 2007 Diisopropyl sulfatecancer2973-10-6 April 1, 1993Diltiazem hydrochloride developmental 33286-22-5 February 27, 2001 3,3’-Dimethoxybenzidine (o -Dianisidine)cancer 119-90-4 January 1, 1988 3,3’-Dimethoxybenzidine dihydrochloride(o -Dianisidine dihydrochloride) cancer 20325-40-0 October 1, 1990 3,3’-Dimethoxybenzidine-based dyes metabolized to 3,3’-dimethoxybenzidinecancer --- June 11, 2004 3,3’-Dimethylbenzidine-based dyes metabolized to 3,3’- dimethylbenzidinecancer ---June 11, 2004 4-Dimethylaminoazobenzene cancer 60-11-7 January 1, 1988 trans -2-[(Dimethylamino)methyl- imino]-5-[2-(5-nitro-2-furyl)vinyl]- 1,3,4-oxadiazolecancer 55738-54-0 January 1, 1988 7,12-Dimethylbenz(a)anthracene cancer 57-97-6 January 1, 1990 3,3’-Dimethylbenzidine (ortho-Tolidine)cancer 119-93-7 January 1, 1988 3,3’-Dimethylbenzidine dihydrochloridecancer 612-82-8 April 1, 1992 Dimethylcarbamoyl chloride cancer 79-44-7 January 1, 1988 1,1-Dimethylhydrazine (UDMH) cancer 57-14-7 October 1, 1989 1,2-Dimethylhydrazine cancer 540-73-8 January 1, 1988 Dimethyl sulfatecancer 77-78-1 January 1, 1988 Dimethylvinylchloride cancer 513-37-1 July 1, 1989 m -Dinitrobenzene male 99-65-0 July 1, 1990 o -Dinitrobenzene male 528-29-0 July 1, 1990 p -Dinitrobenzenemale 100-25-4 July 1, 1990 3,7-Dinitrofluoranthene cancer 105735-71-5 August 26, 1997 3,9-Dinitrofluoranthene cancer 22506-53-2 August 26, 1997 1,6-Dinitropyrene cancer 42397-64-8 October 1, 1990 1,8-Dinitropyrenecancer42397-65-9 October 1, 1990 Dinitrotoluene (technical grade) female, male --- August 20, 1999 Dinitrotoluene mixture, 2,4-/2,6- cancer ---May 1, 1996 2,4-Dinitrotoluenecancer male121-14-2July 1, 1988 August 20, 19992,6-Dinitrotoluenecancer male606-20-2 July 1, 1995 August 20, 1999 Dinocap developmental39300-45-3 April 1, 1990 Dinoseb developmental, male 88-85-7 January 1, 1989 1,4-Dioxanecancer 123-91-1 January 1, 1988 Diphenylhydantoin (Phenytoin) cancerdevelopmental 57-41-0 January 1, 1988 July 1, 1987 Diphenylhydantoin (Phenytoin), sodium saltcancer 630-93-3 January 1, 1988 Di-n -propyl isocinchomeronate (MGK Repellent 326)cancer 136-45-8 May 1, 1996 Direct Black 38 (technical grade) cancer 1937-37-7 January 1, 1988 Direct Blue 6 (technical grade) cancer 2602-46-2 January 1, 1988 Direct Brown 95 (technical grade) cancer16071-86-6 October 1, 1988 Disodium cyanodithio- imidocarbonate developmental 138-93-2 March 30, 1999 Disperse Blue 1 cancer 2475-45-8 October 1, 1990 Diuroncancer 330-54-1 May 31, 2002 Doxorubicin hydrochloride (Adriamycin)cancer25316-40-9 July 1, 1987 Doxorubicin hydrochloride (Adriamycin)developmental, male 25316-40-9 January 29, 1999 Doxycycline (internal use)developmental 564-25-0 July 1, 1990 Doxycycline calcium (internal use) developmental 94088-85-4 January 1, 1992 Doxycycline hyclate (internal use) developmental 24390-14-5 October 1, 1991 Doxycycline monohydrate (internal use) developmental 17086-28-1 October 1, 1991Endrindevelopmental 72-20-8 May 15, 1998 Environmental tobacco smoke (ETS)developmental --- June 9, 2006 Epichlorohydrin cancer male106-89-8 October 1, 1987 September 1, 1996 Ergotamine tartrate developmental 379-79-3 April 1, 1990 Erionitecancer12510-42-8/ 66733-21-9 October 1, 1988 Estradiol 17B cancer 50-28-2 January 1, 1988 Estragolecancer 140-67-0 October 29, 1999 Estrogens, steroidal cancer ---August 19, 2005 Estrone cancer53-16-7 January 1, 1988 Estropipate cancer, developmental 7280-37-7 August 26, 1997 Ethinylestradiol cancer57-63-6 January 1, 1988 Ethionamide developmental 536-33-4 August 26, 1997 Ethoprop cancer 13194-48-4 February 27, 2001 Ethyl acrylatecancer140-88-5 July 1, 1989 Ethyl alcohol in alcoholic beverages developmental ---October 1, 1987 Ethylbenzenecancer 100-41-4 June 11, 2004Ethyl-tert-butyl ethermale637-92-3 December 18, 2009 Ethyl dipropylthiocarbamate developmental 759-94-4 April 27, 1999 Ethyl-4,4’-dichlorobenzilatecancer510-15-6January 1, 1990Ethylene dibromidecancerdevelopmental, male 106-93-4 July 1, 1987 May 15, 1998 Ethylene dichloride (1,2-Dichloroethane)cancer107-06-2 October 1, 1987 Ethylene glycol monoethyl ether developmental, male 110-80-5 January 1, 1989 Ethylene glycol monoethyl ether acetatedevelopmental, male 111-15-9 January 1, 1993 Ethylene glycol monomethyl ether developmental, male 109-86-4 January 1, 1989 Ethylene glycol monomethyl ether acetate developmental, male 110-49-6 January 1, 1993 Ethyleneimine cancer 151-56-4 January 1, 1988 Ethylene oxide cancer female75-21-8 July 1, 1987February 27, 1987developmental, maleAugust 7, 2009 Ethylene thiourea cancerdevelopmental 96-45-7 January 1, 1988 January 1, 1993 2-Ethylhexanoic acid developmental 149-57-5 August 7, 2009 Ethyl methanesulfonate cancer62-50-0 January 1, 1988 Etodolac developmental, female 41340-25-4 August 20, 1999 Etoposide developmental 33419-42-0 July 1, 1990 Etretinate developmental 54350-48-0 July 1, 1987Fenoxaprop ethyl developmental 66441-23-4 March 26, 1999 Fenoxycarb cancer72490-01-8 June 2, 2000Filgrastimdevelopmental 121181-53-1 February 27, 2001 Fluazifop butyl developmental69806-50-4 November 6, 1998 Flunisolide developmental, female 3385-03-3 May 15, 1998 Fluorouracildevelopmental 51-21-8 January 1, 1989 Fluoxymesteronedevelopmental 76-43-7 April 1, 1990 Flurazepam hydrochloride developmental1172-18-5 October 1, 1992 Flurbiprofen developmental, female 5104-49-4 August 20, 1999 Flutamidedevelopmental 13311-84-7 July 1, 1990 Fluticasone propionate developmental 80474-14-2 May 15, 1998Fluvalinate developmental 69409-94-5 November 6, 1998 Folpetcancer 133-07-3 January 1, 1989 Formaldehyde (gas)cancer 50-00-0 January 1, 1988 2-(2-Formylhydrazino)-4- (5-nitro-2-furyl)thiazole cancer3570-75-0 January 1, 1988 Fumonisin B 1 cancer 116355-83-0 November 14, 2003 Furancancer 110-00-9 October 1, 1993 Furazolidone cancer 67-45-8 January 1, 1990 Furmecyclox cancer 60568-05-0 January 1, 1990 Fusarin C cancer 79748-81-5 July 1, 1995Gallium arsenide cancer1303-00-0 August 1, 2008 Ganciclovircancer, developmental, male82410-32-0 August 26, 1997 Ganciclovir sodiumdevelopmental, male 107910-75-8 August 26, 1997 Gasoline engine exhaust (condensates/extracts)cancer---October 1, 1990Gemfibrozilcancerfemale, male 25812-30-0 December 22, 2000 August 20, 1999 Glasswool fibers (airborne particles of respirable size)cancer ---July 1, 1990 Glu-P-1 (2-Amino-6-methyldipyrido [1,2- a:3’,2’-d]imidazole) cancer 67730-11-4 January 1, 1990 Glu-P-2 (2-Aminodipyrido [1,2-a:3’,2’-d]imidazole) cancer67730-10-3 January 1, 1990 Glycidaldehyde cancer 765-34-4 January 1, 1988 Glycidolcancer556-52-5 July 1, 1990 Goserelin acetate developmental, female, male 65807-02-5 August 26, 1997 Griseofulvincancer 126-07-8 January 1, 1990 Gyromitrin (Acetaldehyde methylformylhydrazone) cancer16568-02-8 January 1, 1988Halazepamdevelopmental 23092-17-3 July 1, 1990 Halobetasol propionate developmental66852-54-8 August 20, 1999 Haloperidol developmental, female 52-86-8 January 29, 1999 Halothane developmental 151-67-7 September 1, 1996 HC Blue 1 cancer 2784-94-3 July 1, 1989 Heptachlorcancerdevelopmental 76-44-8 July 1, 1988 August 20, 1999 Heptachlor epoxidecancer 1024-57-3 July 1, 1988 Herbal remedies containing plant species of the genus Aristolochia cancer --- July 9, 2004 Hexachlorobenzenecancerdevelopmental 118-74-1 October 1, 1987 January 1, 1989 Hexachlorocyclohexane (technical grade)cancer ---October 1, 1987 Hexachlorodibenzodioxin cancer 34465-46-8 April 1, 1988 Hexachloroethanecancer 67-72-1 July 1, 1990 2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer) cancer--- March 4, 2005 Hexafluoroacetonemale 684-16-2 August 1, 2008 Hexamethylphosphoramide cancer male680-31-9 January 1, 1988 October 1, 1994 Histrelin acetate developmental---May 15, 1998 Hydramethylnon developmental, male 67485-29-4 March 5, 1999 Hydrazinecancer 302-01-2 January 1, 1988 Hydrazine sulfate cancer 10034-93-2 January 1, 1988 Hydrazobenzene (1,2-Diphenylhydrazine)cancer122-66-7 January 1, 1988 1-Hydroxyanthraquinone cancer129-43-1 May 27, 2005 Hydroxyurea developmental 127-07-1 May 1, 1997Idarubicin hydrochloride developmental, male 57852-57-0 August 20, 1999 Ifosfamide developmental 3778-73-2 July 1, 1990 Iodine-131developmental 10043-66-0 January 1, 1989 Indeno[1,2,3-cd]pyrenecancer193-39-5January 1, 1988Indium phosphidecancer 22398-80-7 February 27, 2001 IQ (2-Amino-3-methylimidazo [4,5-f] quinoline) cancer 76180-96-6 April 1, 1990 Iprodione cancer 36734-19-7 May 1, 1996 Iprovalicarbcancer 140923-17-7 140923-25-7 June 1, 2007 Iron dextran complex cancer 9004-66-4 January 1, 1988 Isobutyl nitrite cancer 542-56-3 May 1, 1996 Isoprenecancer 78-79-5 May 1, 1996 Isosafrole Delisted December 8, 2006 cancer120-58-1 October 1, 1989 Isotretinoin developmental 4759-48-2 July 1, 1987Isoxaflutole cancer 141112-29-0 December 22, 2000Lactofen cancer 77501-63-4 January 1, 1989 Lasiocarpine cancer303-34-4 April 1, 1988Leaddevelopmental, female, male ---February 27, 1987 Lead and lead compounds cancer ---October 1, 1992 Lead acetate cancer 301-04-2 January 1, 1988 Lead phosphate cancer 7446-27-7 April 1, 1988 Lead subacetate cancer1335-32-6 October 1, 1989 Leuprolide acetatedevelopmental, female, male74381-53-6 August 26, 1997 Levodopadevelopmental 59-92-7 January 29, 1999 Levonorgestrel implantsfemale 797-63-7 May 15, 1998 Lindane and other hexachloro- cyclohexane isomers cancer ---October 1, 1989 Linurondevelopmental 330-55-2 March 19, 1999 Lithium carbonate developmental 554-13-2 January 1, 1991 Lithium citrate developmental 919-16-4 January 1, 1991 Lorazepam developmental 846-49-1 July 1, 1990 Lovastatin developmental 75330-75-5 October 1, 1992 Lynestrenol cancer 52-76-6 February 27, 2001Mancozeb cancer 8018-01-7 January 1, 1990 Manebcancer 12427-38-2 January 1, 1990 Marijuana smokecancer ---June 19, 2009 Me-A-alpha-C (2-Amino-3-methyl- 9H-pyrido[2,3-b]indole) cancer 68006-83-7 January 1, 1990 Mebendazoledevelopmental 31431-39-7 August 20, 1999 Medroxyprogesterone acetate cancerdevelopmental 71-58-9 January 1, 1990 April 1, 1990 Megestrol acetatedevelopmental 595-33-5 January 1, 1991 MeIQ (2-Amino-3,4-dimethyl- imidazo[4,5-f]quinoline)cancer 77094-11-2 October 1, 1994 MeIQx (2-Amino-3,8-dimethyl- imidazo[4,5-f]quinoxaline) cancer 77500-04-0 October 1, 1994 Melphalan cancerdevelopmental 148-82-3 February 27, 1987 July 1, 1990 Menotropinsdevelopmental9002-68-0April 1, 1990。